Founded in 1999, Chengda Pharmaceutical Co., Ltd. is a high-tech enterprise with R&D, production and sales of pharmaceutical intermediates, chemical ingredients, food and feed additives as its main business. It was listed in Shenzhen Stock Exchange in 2022 (stock code :301201).
The company is committed to providing CDMO services such as process development and optimization, quality research and customized production of key pharmaceutical intermediates and bulk drugs for multinational pharmaceutical enterprises and pharmaceutical R&D institutions in the clinical trial and commercialization stage of drugs. Terminal drugs involve anti-tumor, antiviral, neurologic, diabetes and other therapeutic fields. The core value of CDMO business of the company is reflected in the development and optimization of pharmaceutical process and industrial application.